Abstract
Gene transfer for the treatment of erectile dysfunction has completed phase 1 safety testing and has shown the necessary safety to proceed to the next level of clinical trial. This review focuses on the background of the components of that have led to US Food and Drug Administration acceptance of human gene transfer trials for nonlethal disease.
Original language | English (US) |
---|---|
Pages (from-to) | 421-426 |
Number of pages | 6 |
Journal | Current urology reports |
Volume | 11 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2010 |
Keywords
- Corpora cavernous
- Erectile dysfunction
- Gene transfer
- Naked DNA, Overactive bladder
- Phase I trial
- Plasmid
- Smooth muscle
ASJC Scopus subject areas
- Urology